Home » in Italy over 31 thousand cases a year with genetic variations. “Precision medicine makes prevention, treatments and research more targeted”

in Italy over 31 thousand cases a year with genetic variations. “Precision medicine makes prevention, treatments and research more targeted”

by admin
in Italy over 31 thousand cases a year with genetic variations.  “Precision medicine makes prevention, treatments and research more targeted”

Italian Summit On Precision Medicine Highlights Importance of Personalized Treatment

The 4th international conference Italian Summit On Precision Medicine took place in Rome, focusing on the importance of implementing personalized diagnostic and therapeutic tools in the field of oncology. Professor Paolo Marchetti emphasized the need to reorganize clinical trials using artificial intelligence, study complex system interactions, and explore the opportunities offered by antibody-conjugated drugs.

According to Professor Marchetti, over 31 thousand new cases of cancer in Italy each year are linked to genetic alterations. The most common types of cancer include breast, colorectal, lung, prostate, and pancreatic cancer. There has been a significant shift in clinical practice towards evaluating genomic variants at the time of diagnosis rather than just in advanced stages of the disease.

Precision medicine is seen as a groundbreaking innovation that can revolutionize the approach to over 200 oncological diseases. With advancements in genetic testing technologies, there is a growing need to personalize anti-tumor treatments for more effective outcomes.

The Italian Summit On Precision Medicine brought together over 150 participants from Europe and the United States to discuss the future of precision oncology. Experts highlighted the need to redesign clinical trials using AI, explore antibody-conjugated drugs for targeted therapies, and study complex system interactions to improve treatment outcomes.

As precision medicine continues to shape the future of oncology research, there are high expectations for its impact on patient care. However, there are also challenges in translating these innovations into everyday clinical practice. Developing evidence-based guidelines and recommendations for specialists will be crucial in ensuring the effective implementation of personalized medicine.

See also  New Drug Donanemab Slows Progression of Alzheimer's Disease, Promising a New Era of Therapy

For more information, contact the Intermedia press office at [email protected] or call 030.226105 – 3487637832.

You may also like

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy